Protective Effect against Neosporosis Induced by Intranasal Immunization with *Neospora caninum* Membrane Antigens Plus Carbomer-Based Adjuvant

Alexandra Correia 1,2*, Pedro Alves 1,2, Ricardo Fróis-Martins 3,4, Luzia Teixeira 5,6 and Manuel Vilanova 1,2,*

1 ICBAS—Instituto de Ciências Biomédicas de Abel Salazar, Universidade do Porto, Rua Jorge Viterbo Ferrera, 4050-313 Porto, Portugal; alexandra.correia@ibmc.up.pt (A.C.); pedro.lc.alves@gmail.com (P.A.)
2 I3S—Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Rua Alfredo Allen, 4200-135 Porto, Portugal
3 Immunology Section, Vetsuisse Faculty, University of Zurich, Winterthurerstrasse 266a, 8057 Zurich, Switzerland; raf.martins@campus.fct.unl.pt
4 Institute of Experimental Immunology, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland
5 UMB—Unidade Multidisciplinar de Investigação Biomédica, ICBAS—Instituto de Ciências Biomédicas de Abel Salazar, Universidade do Porto, Rua de Jorge Viterbo Ferrera, 4050-313 Porto, Portugal; lnteixeira@ibcas.up.pt
6 ITR—Laboratory for Integrative and Translational Research in Population Health, 4050-290 Porto, Portugal

* Correspondence: vilanova@ibcas.up.pt

Abstract: *Neospora caninum* is an obligate intracellular protozoan responsible for abortion and stillbirths in cattle. We previously developed a mucosal vaccination approach using *N. caninum* membrane proteins and CpG adjuvant that conferred long-term protection against neosporosis in mice. Here, we have extended this approach by alternatively using the carbomer-based adjuvant Carbigen™ in the immunizing preparation. Immunized mice presented higher proportions and numbers of memory CD4+ and CD8+ T cells. Stimulation of spleen, lungs and liver leukocytes with parasite antigens induced a marked production of IFN-γ and IL-17A and, less markedly, IL-4. This balanced response was also evident in that both parasite-specific IgG1 and IgG2c were raised by immunization, together with specific intestinal IgA. Upon intraperitoneal infection with *N. caninum*, immunized mice presented lower parasitic burdens than sham-immunized controls. In the infected immunized mice, memory CD4+ T cells predominantly expressed T-bet and RORγt, and CD8+ T cells expressing T-bet were found increased. While spleen, lungs and liver leukocytes of both immunized and sham-immunized infected animals produced high amounts of IFN-γ, only the cells from immunized mice responded with high IL-17A production. Since in cattle both IFN-γ and IL-17A have been associated with protective mechanisms against *N. caninum* infection, the elicited cytokine profile obtained using Carbigen™ as adjuvant indicates that it could be worth exploring for bovine neosporosis vaccination.

Keywords: *Neospora caninum*; vaccine; adjuvant; interferon-γ; interleukin-17

1. Introduction

The apicomplexan *Neospora caninum* is an obligatory intracellular coccidian parasite. Domestic and wild canids are the definitive hosts of *N. caninum* while farm ruminants are the economically important definitive hosts of this parasite, which has been also isolated from horses, deer and buffaloes [1]. *N. caninum* is a major causative agent of abortion and stillbirths in cattle [2]. Neosporosis is prevalent worldwide [1] and inflicts high economic losses to dairy cattle systems [3,4], which have been estimated above one billion US dollars per annum [5]. A recent meta-analysis study estimated that the highest prevalence of bovine neosporosis occurs in North, Central and South America, followed by
Asia, Europe, and Oceania [6]. The highly effective vertical transmission of *N. caninum* in cattle significantly contributes to the burden of disease [7,8]. Several control measures could be considered to manage neosporosis, ranging from “doing nothing” to “test-and-cull” and chemotherapeutical approaches [9,10]. However, vaccination is still considered the most cost-effective approach to manage neosporosis, especially in high-prevalence farms [11]. Currently, no commercial vaccine is available to prevent or treat *N. caninum* infection, despite several approaches that have been attempted to achieve it [12]. A Th1-type response mediated by the IL-12/IFN-γ axis has been considered the prototypic protective immune response in *N. caninum*-infected hosts [13]. Indeed, numerous studies in different host species have associated the production of IFN-γ to protection against neosporosis [13,14].

Studies in mice showed the preponderant role of IFN-γ produced by CD4+ and CD8+ T cells in protection against this parasitic infection [15,16]. Moreover, a direct effect of this cytokine in limiting parasite multiplication in bovine cells has also been demonstrated [17]. Stimulation of nitric oxide production and of immunity-related GTPases and guanyl-ate-binding proteins have been highlighted as effector mechanisms triggered by IFN-γ [16,18–22]. More recently, a protective role of IL-17A against *N. caninum* infection in the bovine model has also been suggested [23,24]. However, a beneficial or deleterious role of this cytokine in the course of infection is yet uncertain [25,26].

Considering the preponderant role of IFN-γ in host protection against neosporosis, several vaccination strategies have stressed the induction of the production of this cytokine through selected antigen and adjuvants [27–32]. We have previously developed a mucosal immunization approach aimed at preventing *N. caninum* infection that used an extract of the parasite membrane antigens together with CpG oligodeoxynucleotide adjuvant to promote Th-1-type and humoral immunity [33]. This approach proved highly effective in protecting against *N. caninum* infection in the long term [34]. Here, we extended our previous work by using the same mucosal immunization approach, using instead the carbomer-based adjuvant Carbigen™ in the immunizing preparation. The low cost of this adjuvant, as compared to previously used CpG, plus its suitability to be used in veterinary immunization [35,36], prompted us to assess its effectiveness in a murine model of neosporosis established intraperitoneally (i.p.). Our results highlighted immune parameters resulting from the immunization approach used here that make Carbigen™ a promising adjuvant to be similarly assessed in the bovine model.

2. Materials and Methods

2.1. Mice

Female C57BL/6 mice were purchased from Charles River (Barcelona, Spain) and bred under specific pathogen-free conditions at the animal facilities of Instituto de Ciências Biomédicas Abel Salazar (ICBAS). Housing and nesting materials were provided as enrichment. Experiments were approved by the institutional board responsible for animal welfare at ICBAS (ORBEA, document 109/2015) and by the competent national authority (DGAV, document 0421/000/000/2016).

2.2. Growth of Parasites and Preparation of Tachyzoite Lysates and Cell Membrane Extracts

*N. caninum* tachyzoites (Nc1 isolate) were serially passaged in VERO cell cultures to obtain free parasitic forms using a previously described methodology [37]. Parasite concentration was determined in cell suspensions using a hemocytometer. Whole parasite sonicates and *N. caninum* antigen extracts enriched in parasite membrane proteins (NeMP) were prepared accordingly to previously described methodology [33]. Briefly, frozen tachyzoites were suspended in PBS containing 0.75% Triton X-14 and the organic phase was precipitated with 4 volumes of absolute ethanol. After centrifugation, the protein extract was air dried and suspended in PBS. Protein concentration was determined using the Pierce™ BCA Protein Assay Kit (Thermo Fisher Scientific, Rockford, IL, USA) according to the manufacturer’s instructions.
2.3. Immunizations and Tissue Sample Collection

Mice, 8–10 weeks-old, randomly distributed into 2 groups, were immunized intranasally (i.n.) with 15 µL of PBS containing 10% of carbomer-based (Carbopol 934P) adjuvant suspension CarbigenTM (MVP adjuvants, Omaha, NE, USA) (CARB group) or with PBS containing 30 µg of NcMP plus 10% CarbigenTM (NcMP/CARB group). A boost immunization was done three weeks later. Three weeks after the boost immunization, mice were either sacrificed by cervical dislocation upon isoflurane anesthesia for organ collection or i.p. challenged with $1 \times 10^7$ N. caninum tachyzoites. Infected mice were similarly sacrificed seven days after infection. Spleens, lungs and liver were collected under aseptic conditions to analyze the elicited immune response. Brain, liver and lungs samples were collected and stored frozen at $-20^\circ$C until processing for DNA extraction. Serum was prepared from clotted blood samples after centrifugation at 10,000 x g for 15 min at 4°C. Serum was then transferred to new tubes and stored frozen at $-20^\circ$C for antibody quantification. Intestinal lavage fluids were prepared as follows: PBS with protease inhibitors (Mini Complete, Roche, Basel, Switzerland) was consecutively passed through the small intestine lumen and then centrifuged at 4500 x g for 15 min at 4°C. The supernatant was collected and centrifuged at 10,000 x g for 1 h at 4°C, and the resulting supernatant was collected and kept frozen at $-20^\circ$C for subsequent antibody detection.

2.4. Antibody Detection

Titers of NcMP-specific serum IgG1 and IgG2c and of IgA in intestinal lavage fluids were quantified by ELISA, using respective alkaline phosphatase-coupled goat anti-mouse antibodies (all from Southern Biotechnology Associates, Birmingham, AL, USA) by a previously described methodology [33].

2.5. In Vitro Cell Cultures and Cytokine Detection

For cytokine production assessment, spleens were mechanically homogenized in Hanks’ balanced salt solution (HBSS) (Sigma) and passed through 100 µm cell strainers (BD Falcon, Franklin Lakes, NJ, USA). Ammonium–Chloride–Potassium Lysing Buffer (ACK) was added to lyse red blood cells. Remaining cells were washed in HBSS and suspended in RPMI-1640 medium supplemented with 10% Fetal Bovine Serum (FBS), HEPES (10 mM), penicillin (200 IU/mL) and streptomycin (200 µg/mL) (all from Sigma, Burlington, MA, USA) (RPMI), and β-mercaptoethanol (0.05 µM) (Merk, Darmstad, Germany). The lungs and livers were cut in small pieces and placed in RPMI containing 2 mg/mL Collagenase D (Roche, Basel, Switzerland) for 45 min at 37°C in a water bath with agitation. Then, samples were homogenized and passed through 100 µm pore cell strainers. Liver leukocytes were isolated through density gradient centrifugation using 33% Percoll (GE Healthcare, Chicago, IL, USA) solution in PBS for 12 min at room temperature at 750 x g with minimal brake. Cells from lungs and liver were washed twice with HBSS 2% FBS before being resuspended in 500 µL supplemented RPMI. In between washes, ACK was added for red blood cell lysis. Spleen, liver and lung cell concentrations were adjusted, and cells were plated (2 x 10^5/well) in round bottom 96-well plates (Nunc, Roskilde, Denmark) and were left unstimulated or stimulated with N. caninum sonicates (25 µg/mL) for 3 days at 37°C and 5% CO2. Then, supernatants were collected for IFN-γ, IL-4, and IL-17A cytokine measurements by ELISA, using respective eBioscience™ Mouse ELISA Ready-SET-Go!TM kits according to manufacturer’ instructions.

2.6. Flow Cytometry Analysis

The following mAbs were used for surface antigen staining: anti-mouse CD3 eFluor 506-conjugate (clone 17A2), anti-mouse CD4 eFluor 450-conjugate (clone RM4–5), anti-mouse CD44 PE-Cy7-conjugate (clone IM7), anti-mouse CD62L PE-conjugate (clone MEL-14) (all from eBioscience, San Diego, CA, USA) and anti-mouse CD8 FITC-conjugate (clone 53-6.7) (BioLegend, San Diego, CA, USA). Cell viability was assessed using APCeFluor 780 Fixable viability dye (FVD; eBioscience). Firstly, cells were stained with FVD and
incubated 30 min on ice. After washing with PBS, antibodies specific for surface markers were added to the cells and incubated for 25 min on ice, protected from light. After washing with FACS buffer (10 mM Sodium Azide, 2% FBS in PBS), cells were fixed with Foxp3 Fixation/Permeabilization solution (eBioscience) and permeabilized using Foxp3 Permeabilization Buffer (eBioscience). For Fcγ receptor nonspecific binding, cells were preincubated with anti-mouse CD16/CD32 (BioLegend) before staining with anti-mouse T-bet PerCP-conjugate (clone eBio4B10), anti-mouse RORγt APC-conjugate (clone B2D), anti-mouse GATA-3 AlexaFluor488-conjugate (clone TWAJ) and anti-granzyme B APC-conjugate (clone NGZB) (all from eBioscience). Fluorescence minus one staining were done for gating purposes. Data were acquired in a BD FACSCanto™ II cytometer (BD Biosciences, Franklin Lakes, NJ, USA) and analyzed using FlowJo version 10.8.1 (Tree Star inc., Ashland, OR, USA). Used gating strategies are shown in Figures S1 and S2.

2.7. DNA Extraction and Real-Time PCR Analysis

DNA was extracted from the brain, liver and lungs of infected mice, as previously described [38]. Parasite burden was assessed by quantitative real-time PCR (qPCR) using the primers NcA 5′-GCTACCAACTCCCCGTTT-3′ and NcS 5′-GTTGCTCTGCTGAAGTTCG-3′, the TaqMan fluorescent probe FAM-CCCGTTCACACACTATAGTCACAAACAAAA-BBQ (all from TIB Molbiol GmbH, Berlin, Germany) and NZY qPCR Probe Master Mix (Nzytech, Lisbon, Portugal). Samples were run in a Corbett rotor gene 6000 system (Corbett Life Science, Sydney, NSW, Australia), according to previously described methods [16]. In all runs, parasite burden was determined by interpolation of a standard curve performed with DNA isolated from N. caninum tachyzoites, ranging from 10 to 1 × 10^−4 ng of parasitic DNA (2 to 2 × 10^5 parasites), included in each run. Data were analyzed in the Rotor gene 6000 software v1.7 (Corbett Life Science) and expressed as log10 parasites per mg of DNA.

2.8. Statistical Analysis

Statistical analyses were performed using GraphPad prism version 9.0 (GraphPad Software, Inc., La Jolla, CA, USA). Scatter dot graphs with bars represent mean and individual values. Test for normal distribution was assessed with Shapiro–Wilk test and Kolmogorov–Smirnov test. When passing normality test data were analyzed using unpaired Student’s t-test. Otherwise, Mann–Whitney test was used, as indicated in figure legends.

3. Results

3.1. T Cell Response to N. caninum Antigens Induced by Immunization

Three weeks after the boost immunization, mice of the NcMP/CARB group presented higher numbers of spleen CD4^+ and CD8^+ T cells displaying a CD44^+CD62L^+ phenotype (Figure 1), characteristic of central memory T cells (T_CM) [39], as compared to the control CARB group. In the spleen and lungs, higher numbers of CD4^+ effector memory (CD44^+CD62L^-) T cells (T_EM) were also found.

Spleen, liver and lung leukocytes from mice of the NcMP/CARB group stimulated ex vivo with N. caninum whole parasite antigen sonicates responded with higher production of IFN-γ and IL-17A, comparatively to similarly stimulated cells obtained from the CARB group mice (Figure 2). Production of IL-4 was also elevated in the cultures of spleen and lung cells of the NcMP/CARB group that was nevertheless detected at lower levels.

Parasite-specific serum IgG1 and IgG2c and intestinal lavage fluid IgA levels were elevated in the NcMP/CARB group as compared to controls (Figure 3). These results altogether demonstrated that the used immunization approach induced a parasite-specific response mediated by T and B cells, characterized by a mixed cytokine profile that was mainly mediated by proinflammatory cytokines IFN-γ and IL-17A, but also involving IL-4 production.
Figure 1. Memory phenotype of CD4+ and CD8+ T cells. Timeline of immunization and sample collection (A). Representative contour plot analysis of gated CD4+ (B) and CD8+ (D) T cells expressing CD44 and CD62L in the indicated organs, 21 days after the boost immunization. Numbers within contour plots correspond to mean percentage values ± SEM for the particular quadrant region in the respective sham-immunized (CARB) or immunized (NcMp/CARB) groups, as indicated. Numbers of CD4+ (C) and CD8+ (E) T cells presenting the cell surface phenotypes CD44+CD62L− and CD44+CD62L+, as indicated, in the analyzed organs of CARB and NcMp/CARB groups. In panels (C,E), bars represent means, and each symbol (black circle) represents an individual mouse ± SEM. Results are of one representative experiment out of two independent experiments that yielded concordant results (n = 4 group; * p < 0.05; ** p < 0.01; *** p < 0.001, unpaired t-test).
Spleen, liver and lung leukocytes from mice of the NcMP/CARB group stimulated ex vivo with *N. caninum* whole parasite antigen sonicates responded with higher production of IFN-γ and IL-17A, comparatively to similarly stimulated cells obtained from the CARB group mice (Figure 2). Production of IL-4 was also elevated in the cultures of spleen and lung cells of the NcMP/CARB group that was nevertheless detected at lower levels.

Figure 2. Analysis of cytokine production. Timeline of immunization and sample collection (A). IFN-γ, IL-17A and IL-4 concentration (B) in the supernatants of leukocyte cell cultures unstimulated (closed circles) or stimulated (open circles) for 3 days with *N. caninum* whole parasite antigen sonicates. Cells were isolated from the spleen, lungs and liver of mice from NcMP/CARB or control CARB groups, as indicated, 21 days after the boost immunization. Each symbol represents an individual mouse; bars correspond to the mean value in each group ± SEM. Results are from one representative experiment out of two independent experiments that yielded concordant results. (n = 4 group; *p* < 0.05, Mann–Whitney.)

3.2. Parasitic Burden in Immunized Mice

To assess whether the induced response could protect against *N. caninum* infection, mice of the CARB and NcMP/CARB groups were infected i.p. with $1 \times 10^7$ *N. caninum* tachyzoites three weeks after the boost immunization. As shown in Figure 4, 7 days upon infection, the NcMP/CARB group presented lower parasitic burdens in the lungs and liver than the sham-immunized CARB group. No significant difference was found in the brain parasitic burden. These results show that the used immunization procedure conferred partial protection against the disseminated *N. caninum* infection established i.p.
Figure 3. Analysis of *N. caninum*-specific antibodies. Timeline of immunization and sample collection (A). Titters of intestinal lavage fluid (ILF) IgA and serum (Serum) IgG1 and IgG2c (B), as indicated, were determined by ELISA in samples collected, on the indicated day, from mice of CARB and NcMP/CARB groups. Data is presented as log_{10} of the antibody titers (n = 4 per group). Each symbol (triangles and circles) represents an individual mouse. Bars correspond to the mean value in each group ± SEM. Results are of one representative experiment out of two independent experiments that yielded concordant results (n = 4 group; * p < 0.05; **** p < 0.0001, Mann–Whitney).

Figure 4. Protective effect of i.n. immunization with NcMP plus Carbigen™ adjuvant against i.p. *N. caninum* infection. Parasitic load was determined through qPCR 7 days upon i.p. challenge with $1 \times 10^7$ *N. caninum* tachyzoites in immunized (NcMP/CARB) or sham-immunized (CARB) mice. Data are presented as log_{10} parasites per mg of total DNA. Results are of one representative experiment out of two independent experiments that yielded concordant results. Each symbol (black circle) represents an individual mouse. Bars correspond to the mean value in each group; (n = 6 group; ** p < 0.01; **** p < 0.0001, unpaired t-test).

3.3. *Parasite-Specific Antibody Levels in Infected Immunized and Nonimmunized Mice*

As shown in Figure 5, 7 days upon infection the levels of parasite-specific serum IgG1 and IgG2c antibodies were found elevated in the NcMP/CARB mouse group comparatively to the CARB group. As observed prior to infection, IgG1 reached higher titers than IgG2c in the immunized group. Parasite-specific IgA levels were also found elevated in intestinal lavage fluids collected from the mice of the NcMP/CARB group as compared to the CARB group. These results showed that the production of parasite-specific antibodies induced by immunization was effective both in the intestinal mucosa and systemically.
Figure 5. Analysis of N. caninum-specific antibodies in infected mice. Timeline of immunization, infection and sample collection (A). Titers of intestinal lavage fluid (ILF) IgA and serum (Serum) IgG1 and IgG2c (B), as indicated, were determined by ELISA in samples collected 7 days after N. caninum i.p. infection from mice previously immunized (NcMP/CARB) or sham-immunized (CARB). Data is presented as log_{10} of the antibody titers. Each symbol (triangles and circles) represents an individual mouse. Bars correspond to the mean value in each group ± SEM. Results are of one representative experiment out of two independent experiments that yielded concordant results. (n = 6 group; ** p < 0.01; *** p < 0.001, Mann-Whitney.)

3.4. Differentiation of T cells Induced in Immunized Mice Infected with N. caninum

As shown in Figure 6B,C, 7 days upon infection, the NcMP/CARB group presented higher proportions and numbers of CD4^+ TEM cells in the spleen. Immunized mice presented higher proportions of CD4^+ TEM cells in the lungs and liver. TEM cell numbers were also found elevated in the lungs of the immunized mice as compared to controls. CD8^+ TEM cells were found at higher proportions in the lungs of NcMP/CARB group mice (Figure 6D) while in the spleen CD8^+ TEM cell proportions and numbers were both found elevated as compared to control group (Figure 6D,E). As expected upon infection, TEM cells predominated in the infected organs.

To determine the type of cellular response induced upon infection in the immunized mice and controls, we evaluated the expression of the transcription factors T-bet, GATA-3 and RORγt, respectively, associated with Th1, Th2 and Th17 cell populations [40] in antigen-experienced (CD44^+) CD4^+ T cells. As shown in Figure 7, immunized mice clearly presented higher proportions and numbers of activated/memory CD4^+ T cells expressing RORγt in all analyzed organs. In the spleen, GATA-3-expressing CD4^+ T cells were also increased in the NcMP/CARB group. Splenic T-bet-expressing CD4^+ T cells were detected at elevated numbers and proportions in immunized mice, although not reaching statistical significance. Similar results were found when evaluating the expression of these transcription factors in gated CD4^+ TEM cells (Figure S3).

Culture supernatants of N. caninum antigen-stimulated NCMP/CARB group lung leukocytes collected 7 days upon N. caninum infection had higher levels of IL-17A (Figure 8), while the levels of IFN-γ and IL-4 did not differ from controls. A bias towards IL-17A production in response to N. caninum antigens was also detected in cultures of liver leukocytes from the NcMP/CARB group. The levels of IFN-γ were also detected elevated in these cultures, however not differing between the NcMP/CARB and CARB groups.

CD8^+ T cells have been also implicated in the protective immune response to acute neosporosis mediated by IFN-γ [16]. Therefore, the expression of T-bet was also assessed in the spleen, liver and lungs of CD44-expressing CD8^+ T cells.
Figure 6. Memory phenotype of CD4+ and CD8+ T cells in infected mice. Timeline of immunization, infection and sample collection (A). Representative contour plot analysis of gated CD4+ (B) and CD8+ (D) T cells expressing CD44 and CD62L in the indicated organs. Numbers within contour plots correspond to mean percentage values ± SEM for the particular quadrant region in the respective sham-immunized (CARB) or immunized (NcMP/CARB) groups, as indicated. Numbers of CD4+ (C) and CD8+ (E) T cells presenting the cell surface phenotypes CD44+CD62L− and CD44+CD62L+, as indicated, in the analyzed organs of CARB and NcMP/CARB groups, 7 days upon N. caninum i.p. infection. In panels (C, E), bars represent means ± SEM. Each symbol (black circle) represents an individual mouse. Results are from one experiment representative of two independent experiments that yielded concordant results (n = 6 group; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001, unpaired t-test).
Figure 7. Expression of T-bet, RORγt and GATA-3 in CD4+CD44+ T cells collected from infected mice. (A) Representative contour plots of T-bet and RORγt expression in CD4+ CD44+ T cells in the indicated organs of sham-immunized (CARB) or immunized (NcMP/CARB) mice, as indicated, 7 days after i.p. challenged with 1 × 10^7 N. caninum tachyzoites. Numbers within contour plots correspond to mean percentage values ± SEM of cells in the respective analysis regions. (B) Numbers of CD4+ CD44+ T cells expressing T-bet, RORγt and GATA-3 in the indicated organs of infected mice of NcMP/CARB and CARB mouse groups. Each symbol (black circle) represents an individual mouse. Results are representative of two independent experiments that yielded concordant results (n = 6 group; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001, Mann–Whitney).

As shown in Figure 9, higher total numbers of spleen T-bet-expressing CD8+CD44+ T cells were detected in the N. caninum infected NcMP/CARB mouse group than in the control group. Higher proportions, but not total numbers, of T-bet-expressing CD8+CD44+ T cells were observed in the liver of immunized mice when compared to controls. No such difference was observed between groups in the lungs, further suggesting the strong polarization towards a Th17-type response induced by the intranasal immunization in this organ. The total numbers of granzyme B-expressing cells were not significantly different between mouse groups. The analysis of the expression of T-bet and granzyme B within the CD8+ T_{EM} cell compartment revealed similar results (Figure S4). Altogether, these results show that immunization with NcMP plus Carbigen® induced the differentiation of Th-1 and Th-17 cells and highlight the impact of the local environment in the elicited response.
Figure 8. Analysis of cytokine production. Timeline of immunization, infection and sample collection (A). IFN-γ, IL-4 and IL-17A concentration (B) in the supernatants of splenocyte cell cultures unstimulated (closed symbols) or stimulated (open symbols) for 3 days with *N. caninum* whole parasite antigen sonicates. Cells were isolated from the spleen, lungs and liver of mice from NcMP/CARB or control CARB groups, as indicated, 7 days after the i.p. challenge with $1 \times 10^7$ *N. caninum* tachyzoites. Each symbol (black and white circles) represents an individual mouse; bars correspond to the mean value in each group ± SEM. Results are representative of two independent experiments that yielded concordant results ($n = 6$ group; * $p < 0.05$; ** $p < 0.01$, Mann–Whitney).
Figure 9. Expression of T-bet and granzyme B in CD8+ T cells of infected mice. (A) Representative contour plot analysis of CD8+ CD44+ T cells expressing T-bet in the indicated organs of sham-immunized (CARB) or immunized (NcMP/CARB) mice, as indicated, 7 days after i.p. challenged with 1 × 10^7 N. caninum tachyzoites. Numbers within contour plots correspond to mean percentage values ± SEM of T-bet expressing cells within the CD8+ CD44+ T cell population. (B) Numbers of CD8+ CD44+ T-bet+ and CD8+CD44+ granzyme B+ cells in the indicated organs of immunized and sham-immunized mice. Each symbol (black circle) represents an individual mouse. Results are representative of two independent experiments that yielded concordant results (n = 6 group; * p < 0.05; ** p < 0.01, unpaired t-test).

4. Discussion

We have previously reported a mucosal immunization approach to prevent neosporosis based on the intranasal administration of an N. caninum membrane antigen extract and CpG adjuvant [33]. This immunization approach was conceived aiming at inducing parasite-specific Th-1-type immunity that is promoted by CpG [41]. It is well established that IL-12 and IFN-γ are key cytokines in host protection from neosporosis, as clearly shown in several genetically deficient murine models [19,42,43]. Using Carbigen™ as the selected adjuvant in the immunization performed here prompted spleen and liver leukocyte cells obtained from the NcMP/CARB group to robustly produce IFN-γ upon N. caninum antigen stimulation. This response may contribute to the protective effect against N. caninum infection observed in that mouse group and concurs with the generation of T-bet+ CD8+ T cells induced by immunization. Indeed, using a similar model of infection, we showed that IFN-γ production, rather than cytotoxicity, was the preponderant CD8+ T cell effector mechanism counteracting N. caninum in the acute phase of infection [16].

T-bet expression in CD8+ T cells has been associated with effector rather than memory cell differentiation [44]. As CD8+ T cells have been implicated in IFN-γ-dependent immunity to N. caninum [16,45], it will be interesting to assess CD8+ T cell function at a longer term in immunized animals. On the other hand, as T-bet has been shown to limit the expression of the inhibitory cell surface receptor programmed cell death protein 1 (PD-1) on CD8+ T cells [46], the higher expression of this transcription factor may help sustain the effector function of these lymphocytes in infected immunized hosts.

A marked production of IL-17A was also induced in the immunized animals. While this cytokine is usually associated with immune protection from fungal and bacterial
infections [47], it can also play a host protective role in diverse protozoan infections [48], including *N. caninum*-related protozoan *Toxoplasma gondii* [49]. Indeed, IL-17 receptor-deficient mice displayed increased mortality when infected with *T. gondii*, which has been attributed to impaired neutrophil recruitment to infected sites [49]. Moreover, the production of IL-17A has been associated with reduced parasitic burden in mice immunized with *T. gondii* protein ROP13 [50]. Here, IL-17A production was evident in parasite antigen-stimulated leukocyte cells obtained from immunized mice prior or after infection. This is in accordance with the observed increase in CD44+CD4+ T cells expressing the Th17-associated marker RORγt in immunized mice. Th17 cells have been particularly implicated in the local protective immune response to pulmonary infections caused by bacteria, fungi or viruses [51]. Moreover, these cells have been implicated in protective mechanisms against protozoan infections [52,53]. It would therefore be worth determining whether these cells could be mediating the pulmonary protective effect observed in the NcMP/CARB mouse group, since IL-17-mediated responses in the lungs induced by intranasal immunization have been previously associated with host protection from diverse infections [54–57]. The intranasal immunization used here also induced *N. caninum* antigen responsive liver leukocyte cells producing IL-17A. Even though local production of this cytokine in that organ may have contributed to the lower parasitic burden, it may also play a regulatory role therein, as previously described in *T. gondii*-infected mice [58]. Although the specific role of this cytokine has not yet been elucidated in the context of *N. caninum* infection, the scarce evidence available indicates that in ruminants, IL-17 may be involved in host protection by mediating parasite elimination [24] or limiting its vertical transmission [23]. These findings support exploring in cattle the immunization strategy addressed here, based on using Carbigen™ adjuvant.

Although we observed here that the used immunization approach conferred partial protection against *N. caninum* infection in the lungs and liver, it did not lead to significantly reduced parasitic burden in the brain, contrasting previous results obtained using CpG adjuvant in a similar i.n. immunization approach [33]. A less exacerbated Th1-type polarization in the immune response induced by the adjuvant used here may have accounted for the absence of a protective effect in the brain tissue.

Antibodies have been previously implicated in host protective mechanisms operating against *N. caninum* infection locally at the intestinal mucosa and systemically [33,34,59]. The results obtained here showed the effectiveness of using Carbigen™ adjuvant to raise parasite-specific intestinal IgA and circulatory IgG levels, which might, respectively, counteract the parasite entry into the host at the intestinal tract and parasite dissemination within the host. The IgG antibodies raised by the immunization presented a mixed IgG1 and IgG2c isotype profile that was detected prior to and after infection, in accordance with the detected production of IL-4 and IFN-γ in the culture supernatants of the antigen-stimulated leukocytes isolated from the NcMP/CARB mice. This cytokine and antibody profile indicate that a balanced immune response was induced by the immunization. A balanced Th1/Th2 response has been considered beneficial in the course of neosporosis in pregnant mouse models by conferring protection against the parasite and avoiding fetal rejection by limiting deleterious excessive inflammation [25]. Moreover, an antibody profile with higher IgG1 than IgG2 antibodies combined with IFN-γ was previously associated with the reduced vertical transmission of *N. caninum* in cattle [60], which further highlights the potential of considering the Carbigen™ adjuvant in future studies of immunization against neosporosis in cattle. Although the murine model has been rightly considered a valuable experimental tool in preclinical studies in neosporosis [61], species-specific immune mechanisms should be accounted when evaluating immunization approaches to this parasitic disease. Additionally, as the immunization approach used here raised parasite specific antibodies in the gut and a balanced immune response, deemed convenient during pregnancy, it would be interesting to assess this immunizing procedure in animal models where infection could be established via the gastrointestinal tract or through vertical transmission.
5. Conclusions

Our results show that intranasal immunization with NcMP as the target antigens plus the Carbigen™ adjuvant promoted a balanced immune response characterized by a preponderant differentiation of RORγt- and T-bet-expressing memory T cells, leading to the predominant production of IFN-γ and IL-17A in response to parasite antigens. In the immunized animals, a lower parasitic burden was detected in the lungs and liver. Although the lack of detected protection in the brain may pose a limitation to this adjuvant, the results reported here indicate that, as previously highlighted by others [24], exploring more in depth the role of IL-17-promoting adjuvants, such as we observed here using Carbigen™, will be nevertheless worth attempting in vaccination approaches to neosporosis.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/vaccines10060925/s1, Figure S1: Flow cytometry gating strategy used to define CD4+ T effector and central memory cells, and the expression of transcription factors; Figure S2. Flow cytometry gating strategy used to define CD8+ T effector and central memory cells, and T-bet and granzyme B expression; Figure S3: Expression of transcription factors T-bet and RORγt in CD4+ TEM cells of infected mice.; Figure S4: Expression of transcription factor T-bet and granzyme B in CD8+ TEM cells of infected mice.

Author Contributions: Conceptualization, A.C. and M.V.; methodology, A.C., L.T. and M.V.; validation, A.C. and M.V.; formal analysis, A.C. and P.A.; investigation, A.C., P.A., R.F.-M., L.T. and M.V.; resources, A.C., L.T. and M.V.; data curation A.C.; writing—original draft preparation, A.C., P.A. and M.V.; writing—review and editing, A.C. and M.V.; visualization, A.C. and P.A.; supervision, A.C. and M.V.; project administration A.C. and M.V.; funding acquisition, A.C. and M.V. All authors have read and agreed to the published version of the manuscript.

Funding: This work was financed by FEDER—Fundo Europeu de Desenvolvimento Regional funds through the COMPETE 2020—Operacional Programme for Competitiveness and Internationalisation (POCI), Portugal 2020, and by Portuguese funds through FCT—Fundaçã o para a Ciência e a Tecnologia/Ministé rio da Ciência, Tecnologia e Ensino Superior in the framework of the project POCI-01-0145-FEDER-31020 (PTDC/CVT-CVT/31020/2017).

Institutional Review Board Statement: Experiments were approved by the institutional board responsible for animal welfare at ICBAS (ORBEA, document 109/2015) and by the competent national authority (DGAV, document 0421/000/000/2016; 2016-06-17 013470).

Informed Consent Statement: Not applicable.

Data Availability Statement: The data presented in this study are available on reasonable request from the corresponding author.

Acknowledgments: The authors acknowledge the support of i3S Scientific Platform Translational Cytometry and ICBAS-UP Animal Facility. The authors would like to express their gratitude to Encarnação Rebelo from ICBAS-UP for excellent technical assistance.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References
1. Dubey, J.; Scharer, G.R.M. Neosporosis in animals—The last five years. Vet. Parasitol. 2011, 180, 90–108. [CrossRef] [PubMed]
2. Lindsay, D.S.; Dubey, J. Neosporosis, Toxoplasmosis, and Sarcocystosis in Ruminants: An Update. Vet. Clin. N. Am. Food Anim. Pract. 2020, 36, 205–222. [CrossRef] [PubMed]
3. Rasmussen, P.; Shaw, A.P.; Muñoz, V.; Bruce, M.; Torgerson, P.R. Estimating the burden of multiple endemic diseases and health conditions using Bayes’ Theorem: A conditional probability model applied to UK dairy cattle. Prev. Vet. Med. 2022, 203, 105617. [CrossRef] [PubMed]
4. Demir, P.A.; Eski, F.; ÜTÜK, A.E. Estimating the total economic costs of Neospora caninum infections in dairy cows in Turkey. Trop. Anim. Health Prod. 2020, 52, 3251–3258. [CrossRef] [PubMed]
5. Reichel, M.P.; Ayanegui-Alcárrez, M.A.; Gondim, L.; Ellis, J. What is the global economic impact of Neospora caninum in cattle—The billion dollar question. Int. J. Parasitol. 2013, 43, 133–142. [CrossRef]
6. Ribeiro, C.M.; Soares, I.R.; Mendes, R.G.; Bastos, P.A.D.S.; Katagiri, S.; Zavilenski, R.B.; de Abreu, H.F.P.; Afreixo, V. Meta-analysis of the prevalence and risk factors associated with bovine neosporosis. *Trop. Anim. Health Prod.* 2019, 51, 1783–1800. [CrossRef]

7. Rojas-Pirela, M.; Medina, L.; Rojas, M.V.; Liempi, A.I.; Castillo, C.; Pérez-Pérez, E.; Guerrero-Muñoz, J.; Araneda, S.; Kemmerling, U. Congenital Transmission of Apicomplexan Parasites: A Review. *Front. Microbiol.* 2021, 12, 751648. [CrossRef]

8. Dubey, J.P.; Scharfs, G.; Ortega-Mora, L.M. Epidemiology and Control of Neosporosis and *Neospora caninum*. *Clin. Microbiol. Rev.* 2007, 20, 323–367. [CrossRef]

9. Sánchez, R.S.; Vazquez, P.; Ferre, I.; Ortega-Mora, L.-M. Treatment of Toxoplasmosis and Neosporosis in Farm Ruminants: State of Knowledge and Future Trends. *Curr. Top. Med. Chem.* 2018, 18, 1304–1323. [CrossRef]

10. Reichel, M.P.; McAllister, M.M.; Pomroy, W.E.; Campero, C.; Ortega-Mora, L.-M.; Ellis, J.T. Control options for *Neospora caninum*—Is there anything new or are we going backwards? *Parasitology* 2014, 141, 1435–1470. [CrossRef]

11. Liu, Y.; Reichel, M.P.; Lo, W.C. Combined control evaluation for *Neospora caninum* infection in dairy: Economic point of view coupled with population dynamics. *Vet. Parasitol.* 2020, 277, 108967. [CrossRef] [PubMed]

12. Monney, T.; Hemphill, A. Vaccines against neosporosis: What can we learn from the past studies? *Exp. Parasitol.* 2014, 140, 52–70. [CrossRef] [PubMed]

13. Fereig, R.M.; Nishikawa, Y. From Signaling Pathways to Distinct Immune Responses: Key Factors for Establishing or Combating *Neospora caninum* Infection in Different Susceptible Hosts. *Pathogens* 2020, 9, 384. [CrossRef] [PubMed]

14. Almería, S.; Serrano-Pérez, B.; López-Gatius, F. Immune response in bovine neosporosis: Protection or contribution to the pathogenesis of abortion. *Microb. Pathog.* 2019, 109, 177–182. [CrossRef] [PubMed]

15. Tanaka, T.; Hamada, T.; Inoue, N.; Nagasawa, H.; Fujisaki, K.; Suzuki, N.; Mikami, T. The role of CD4⁺ or CD8⁺ T cells in the protective immune response of BALB/c mice to *Neospora caninum* infection. *Vet. Parasitol.* 2000, 90, 183–191. [CrossRef]

16. Correia, A.; Ferreirinha, P.; Botelho, S.; Belinha, A.; Leitão, P.; Guimarães, P.; et al. Comparative Genomics of the Apicomplexan Parasites *Toxoplasma gondii* and *Neospora caninum*. *PLoS Pathog.* 2012, 8, e1002567. [CrossRef] [PubMed]

17. Yamane, I.; Kitani, H.; Kokuhodo, T.; Shibahara, T.; Haritani, T.; Shibahara, T.; et al. The inhibitory Effect of Interferon Gamma and Tumor Necrosis Factor Alpha on Intracellular Multiplication of *Neospora caninum* in Primary Bovine Brain Cells. *J. Vet. Med. Sci.* 2000, 62, 347–351. [CrossRef]

18. Tanaka, T.; Nagasawa, H.; Fujisaki, K.; Suzuki, N.; Mikami, T. Growth-inhibitory effects of interferon-γ on *Neospora caninum* in murine macrophages by a nitric oxide mechanism. *Parasitol. Res.* 2006, 98, 768–771. [CrossRef]

19. Nishikawa, Y.; Tragoolpua, K.; Inoue, N.; Makala, L.; Nagasawa, H.; Otsuka, H.; Mikami, T. In the Absence of Endogenous Gamma Interferon, Mice Acutely Infected with *Neospora caninum* Succumb to a Lethal Immune Response Characterized by Inactivation of Peritoneal Macrophages. *Clin. Diagn. Lab. Immunol.* 2001, 8, 811–816. [CrossRef]

20. Barros, P.D.S.C.; Mota, C.M.; Miranda, V.D.S.; Ferreira, F.B.; Ramos, E.L.P.; Santana, S.S.; Costa, L.F.; Pajuaba, A.C.A.M.; Mineo, J.R.; Mineo, T.W.P. Inducible Nitric Oxide Synthase is required for parasite restriction and inflammatory modulation during *Neospora caninum* infection. *Vet. Parasitol.* 2019, 276, 108990. [CrossRef] [PubMed]

21. Spekker, K.; Leineweber, M.; Degrandi, D.; Ince, V.; Bruder, S.; Schmidt, S.K.; Stuhlsatz, S.; Howard, J.C.; Scharfs, G.; Degistirici, O.; et al. Antimicrobial effects of murine mesenchymal stromal cells directed against Toxoplasma gondii and *Neospora caninum*: Role of immunity-related GTPases (IRGs) and guanylate-binding proteins (GBPs). *Med. Microbiol. Immunol.* 2012, 202, 197–206. [CrossRef] [PubMed]

22. Reid, A.J.; Vermont, S.J.; Cotton, J.A.; Harris, D.; Hill-Cawthorne, G.A.; Könen-Waisman, S.; Latham, S.M.; Mourier, T.; Norton, R.; Quail, M.A.; et al. Comparative Genomics of the Apicomplexan Parasites Toxoplasma gondii and Neospora caninum: Coccidia Differing in Host Range and Transmission Strategy. *PLoS Pathog.* 2012, 8, e1002567. [CrossRef] [PubMed]

23. Gutiérrez-Expósito, D.; González-Warleta, M.; Espinosa, J.; Vallejo-García, R.; Castro-Hermida, J.A.; Calvo, C.; Ferreras, M.C.; Pérez, V.; Benavides, J.; Mezo, M. The maternal immune response in the placenta of sheep during recrudescence of natural congenital infection of *Neospora caninum*. *Vet. Parasitol.* 2020, 285, 109204. [CrossRef] [PubMed]

24. Peckham, R.K.; Brill, R.; Foster, D.; Bowen, A.L.; Leigh, J.; Coffey, T.; Flynn, R.J. Two distinct populations of Bovine IL-17⁺ T-cells can be induced and WC1⁺IL-17⁺γδ T-cells are effective killers of protozoan parasites. *Sci. Rep.* 2014, 4, 5431. [CrossRef]

25. Debache, K.; Hemphill, A. Parasite limiting macrophages promote IL-17 secretion in naïve bovine CD4⁺ T-cells during *Neospora caninum* infection. *Parasite Immunol.* 2012, 35, 11–20. [CrossRef]

26. Flynn, R.J.; Marshall, E.S. Parasite limiting macrophages promote IL-17 secretion in naïve bovine CD4⁺ T-cells during *Neospora caninum* infection. *Vet. Immunol. Immunopathol.* 2011, 144, 423–429. [CrossRef]

27. U. Congenital Transmission of Apicomplexan Parasites: A Review. *Trop. Anim. Health Prod.* 2021, 52, 357–367. [CrossRef]

28. Mansilla, F.C.; Franco-Mahecha, O.L.; Lavoria, M.; Moore, D.; Giraldiez, A.N.; Iglesias, M.E.; Wilda, M.; Capozzo, A.V. The immune enhancement of a novel soy lecithin/β-glucans based adjuvant on native *Neospora caninum* tachyzoite extract vaccine in mice. *Vaccine* 2012, 30, 1124–1131. [CrossRef]

29. Monney, T.; Rütti, D.; Schorzer, M.; Debache, K.; Grandgirard, D.; Leib, S.L.; Hemphill, A. RecNeMiC3-1-R is a micromere- and rhoptry-based chimeric antigen that protects against acute neosporosis and limits cerebral parasite load in the mouse model for *Neospora caninum* infection. *Vaccine* 2011, 29, 6967–6975. [CrossRef]
30. Williams, D.J.L.; Guy, C.S.; Smith, R.F.; Ellis, J.; Björkman, C.; Reichel, M.P.; Trees, A.J. Immunization of Cattle with Live Tachyzoites of Neospora caninum Confers Protection against Fetal Death. *Infect. Immun.* 2007, 75, 1343–1348. [CrossRef]

31. Staska, L.M.; Davies, C.J.; Brown, W.C.; McGuire, T.C.; Suarez, C.E.; Park, J.Y.; Mathison, B.A.; Abbott, J.R.; Baszler, T.V. Identification of Vaccine Candidate Peptides in the NeSRS2 Surface Protein of Neospora caninum by Using CD4+ Cytotoxic T Lymphocytes and Gamma Interferon-Secreting T Lymphocytes of Infected Holstein Cattle. *Infect. Immun.* 2005, 73, 1321–1329. [CrossRef] [PubMed]

32. Andrianiarivo, A.; Choromanski, L.; McDonough, S.; Packham, A.; Conrad, P. Immunogenicity of a killed whole Neospora caninum tachyzoite preparation formulated with different adjuvants. *Int. J. Parasitol.* 1999, 29, 1613–1625. [CrossRef]

33. Ferreirinha, P.; Dias, J.; Correia, A.; Pérez-Cabezas, B.; Santos, C.; Teixeira, L.; Ribeiro, A.; Rocha, A.; Vilanova, M. Protective effect of intranasal immunization with Neospora caninum membrane antigens against murine neosporosis established through the gastrointestinal tract. *Immunology* 2014, 141, 256–267. [CrossRef] [PubMed]

34. Ferreirinha, P.; Correa, A.; Teixeira-Coelho, M.; Osório, H.; Teixeira, L.; Rocha, A.; Vilanova, M. Mucosal immunization confers long-term protection against intragastrically established *Neospora caninum* infection. *Vaccine* 2016, 34, 6250–6258. [CrossRef] [PubMed]

35. Park, M.-E.; Lee, S.-Y.; Kim, R.-H.; Ko, M.-K.; Lee, K.-N.; Kim, S.-M.; Kim, B.-K.; Lee, J.-S.; Kim, B.; Park, J.-H. Enhanced immune responses of foot-and-mouth disease vaccine using new oil/gel adjuvant mixtures in pigs and goats. *Vaccine* 2014, 32, 5221–5227. [CrossRef]

36. Peters, J.L.; DeMars, P.L.; Collins, L.M.; Stoner, J.A.; Matsumoto, H.; Komori, N.; Singh, A.; Feasley, C.L.; Haddock, J.A.; Levine, M. Effects of immunization with natural and recombinant lysine decarboxylase on canine gingivitis development. *Vaccine* 2012, 30, 6706–6712. [CrossRef]

37. Teixeira, L.; Botelho, A.S.; Mesquita, S.D.; Correia, A.; Cerca, F.; Costa, R.; Sampaio, P.; Castro, G.; Vilanova, M. Plasmacytoid and conventional dendritic cells are early producers of IL-12 in *Neospora caninum*-infected mice. *Immunol. Cell Biol.* 2009, 88, 79–86. [CrossRef]

38. Nishihawa, Y.; Inoue, N.; Xuan, X.; Nagasawa, H.; Igarashi, I.; Fujisaki, K.; Otsuka, H.; Mikami, T. Protective efficacy of vaccination by recombinant vaccinia virus against *Neospora caninum* infection. *Vaccine* 2001, 19, 1381–1390. [CrossRef]

39. Williams, M.A.; Bevan, M.J. Effector and Memory CTL Differentiation. *Annu. Rev. Immunol.* 2007, 25, 171–192. [CrossRef]

40. Raphael, I.; Nalawade, S.; Eagar, T.N.; Forsthuber, T.G. T cell subsets and their signature cytokines in autoimmune and inflammatory diseases. *Cytokine* 2014, 75, 5–17. [CrossRef]

41. Shirota, H.; Klinman, D.M. Recent progress concerning CpG DNA and its use as a vaccine adjuvant. *Expert Rev. Vaccines* 2013, 13, 299–312. [CrossRef] [PubMed]

42. Botelho, A.; Teixeira, L.; Correia-Da-Costa, J.; Faustino, A.; Castro, A.; Vilanova, M. *Neospora caninum*: High susceptibility to the parasite in C57BL/10ScCr mice. *Exp. Parasitol.* 2007, 115, 68–75. [CrossRef]

43. Mineo, T.W.; Benevides, L.; Silva, N.M.; Silva, J.S. Myeloid differentiation factor 88 is required for resistance to *Neospora caninum* infection. *Vet. Res.* 2009, 40, 32. [CrossRef] [PubMed]

44. Kallies, A.; Good-Jacobson, K.L. Transcription Factor T-bet Orchestrates Lineage Development and Function in the Immune System. *Trends Immunol.* 2017, 38, 287–297. [CrossRef]

45. Correia, A.; Ferreirinha, P.; Costa, A.A.; Dias, J.; Melo, J.; Costa, R.; Ribeiro, A.; Faustino, A.; Teixeira, L.; Rocha, A.; et al. Mucosal and systemic T cell response in mice intragastrically infected with *Neospora caninum* tachyzoites. *Vet. Res.* 2013, 44, 69. [CrossRef] [PubMed]

46. Kao, C.; Oestreicher, K.J.; Paley, M.; Crawford, A.; Angelosanto, J.M.; Ali, M.-A.A.; Intlekofer, A.; Boss, J.M.; Reiner, S.L.; Weinmann, A.S.; et al. Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infection. *Nat. Immunol.* 2011, 12, 663–671. [CrossRef]

47. Valeri, M.; Raffatelli, M. Cytokines IL-17 and IL-22 in the host response to infection. *Pathog. Dis.* 2016, 74, ftw111. [CrossRef]

48. Vesely, M.C.A.; Rodríguez, C.; Gruppi, A.; Rodríguez, E.V.A. Interleukin-17 mediated immunity during infections with Trypanosoma cruzi and other protozoans. *Biochim. Biophys. Acta Mol. Basis Dis.* 2020, 1866, 165706. [CrossRef]

49. Kelly, M.N.; Kolls, J.K.; Kaplan, H.; Schwartzman, J.D.; Schwarzenberger, P.; Combe, C.; Moretto, M.; Khan, I.A. Interleukin-17/Interleukin-17 Receptor-Mediated Signaling Is Important for Generation of an Optimal Polymorphonuclear Response against *Toxoplasma gondii* infection. *Infect. Immun.* 2005, 73, 617–621. [CrossRef]

50. Alizadeh, P.; Ahmadpour, E.; Daryani, A.; Kazemi, T.; Spotin, A.; Mahami-Oskouei, M.; Flynn, R.J.; Azadi, Y.; Rajabi, S.; Sandoghchian, S. IL-17 and IL-22 elicited by a DNA vaccine encoding ROP13 associated with protection against *Neospora caninum* infection in BALB/c mice. *J. Cell. Physiol.* 2018, 234, 10782–10788. [CrossRef]

51. Rathore, J.S.; Wang, Y. Protective role of Th17 cells in pulmonary infection. *Vaccine* 2016, 34, 1504–1514. [CrossRef] [PubMed]

52. Banerjee, A.; Bhattacharya, P.; Dagur, P.K.; Karmakar, S.; Ismail, N.; Joshi, A.B.; Akue, A.D.; KuKuruga, M.; McCoy, J.P.; Dey, R.; et al. Live Attenuated *Leishmania donovani* Centrin Gene–Deleted Parasites Induce IL-23–Dependent IL-17–Protective Immune Response against Visceral Leishmaniasis in a Murine Model. *J. Immunol.* 2017, 200, 163–176. [CrossRef] [PubMed]

53. Miyazaki, Y.; Hamano, S.; Wang, S.; Shimanoe, Y.; Iwakura, Y.; Yoshida, H. IL-17 Is Necessary for Host Protection against Acute-Phase *Trypanosoma cruzi* Infection. *J. Immunol.* 2010, 185, 1150–1157. [CrossRef] [PubMed]
54. Allen, A.C.; Wilk, M.; Misiak, A.; Borkner, L.; Murphy, D.; Mills, K.H.G. Sustained protective immunity against Bordetella pertussis nasal colonization by intranasal immunization with a vaccine-adjuvant combination that induces IL-17-secreting TRM cells. *Mucosal Immunol.* **2018**, *11*, 1763–1776. [CrossRef] [PubMed]

55. Sen-Kilic, E.; Blackwood, C.; Boehm, D.T.; Witt, W.T.; Malkowski, A.C.; Bevere, J.R.; Wong, T.Y.; Hall, J.M.; Bradford, S.; Varney, M.; et al. Intranasal Peptide-Based FpvA-KLH Conjugate Vaccine Protects Mice From Pseudomonas aeruginosa Acute Murine Pneumonia. *Front. Immunol.* **2019**, *10*, 2497. [CrossRef] [PubMed]

56. Cabral, M.P.; Correia, A.; Vilanova, M.; Gärtner, M.D.F.; Moscoso, M.; García, P.; Vallejo, J.A.; Pérez, A.; Francisco-Tomé, M.; Fuentes-Valverde, V.; et al. A live auxotrophic vaccine confers mucosal immunity and protection against lethal pneumonia caused by *Pseudomonas aeruginosa*. *PLoS Pathog.* **2020**, *16*, e1008311. [CrossRef] [PubMed]

57. Ashtekar, A.R.; Katz, J.; Xu, Q.; Michalek, S.M. A Mucosal Subunit Vaccine Protects against Lethal Respiratory Infection with *Francisella tularensis* LVS. *PLoS ONE* **2012**, *7*, e50460. [CrossRef] [PubMed]

58. Moroda, M.; Takamoto, M.; Iwakura, Y.; Nakayama, J.; Aosai, F. Interleukin-17A-Deficient Mice Are Highly Susceptible to *Toxoplasma gondii* Infection Due to Excessively Induced T. gondii HSP70 and Interferon Gamma Production. *Infect. Immun.* **2017**, *85*, e00399-17. [CrossRef] [PubMed]

59. Ferreirinha, P.; Fróis-Martins, R.; Teixeira, L.; Rocha, A.; Vilanova, M.; Correia, A. Interferon-γ-dependent protection against *Neospora caninum* infection conferred by mucosal immunization in IL-12/IL-23 p40-deficient mice. *Vaccine* **2018**, *36*, 4890–4896. [CrossRef] [PubMed]

60. Pereyra, R.; Mansilla, F.C.; Petersen, M.I.; Suarez, V.; Capozzo, A.V. Evidence of reduced vertical transmission of *Neospora caninum* associated with higher IgG1 than IgG2 serum levels and presence of IFN-γ in non-aborting chronically infected cattle under natural condition. *Vet. Immunol. Immunopathol.* **2019**, *208*, 53–57. [CrossRef] [PubMed]

61. Aguado-Martinez, A.; Basto, A.; Leitao, A.; Hemphill, A. *Neospora caninum* in non-pregnant and pregnant mouse models: Cross-talk between infection and immunity. *Int. J. Parasitol.* **2017**, *47*, 723–735. [CrossRef] [PubMed]